Saluda Medical Presents New Clinical Findings
Saluda Medical, Inc., a leader in innovative neuromodulation technologies aimed at enhancing the lives of individuals with chronic neurological conditions, recently showcased exciting new clinical data at a significant meeting. This event was organized by the North American Neuromodulation Society (NANS) and provided a platform to share research highlighting the potential of their automated spinal cord stimulation (SCS) programming platform, known as EVA™.
Understanding EVA™ and Its Clinical Impact
The clinical data presented comprise 11 abstracts and four oral presentations, shedding light on the importance of neurophysiological metrics in spinal cord stimulation. Notably, two of the oral presentations earned the esteemed "Top Oral Abstract" award. These findings emphasize the substantial benefits of the newly FDA-approved EVA™ platform, designed for automated patient programming, which can lead to better patient outcomes in chronic pain management.
Highlights from the Clinical Abstracts
A standout abstract presented by Dr. Ajay Anthony focused on the EVA™ platform’s efficacy. In his prospective study, he revealed that a remarkable 94% of programming sessions using the automated platform achieved successful closed-loop configurations. Moreover, the median time taken to create a personalized automated program was an impressive 13 minutes or less, with more than 90% of patients expressing satisfaction with their programming experience.
Insights from Top Oral Abstract Presentations
Dr. Jason Pope highlighted findings from a significant real-world study involving 220 patients. His research illustrated a robust link between physiological ECAP biomarkers and pain management outcomes across various categories, including conditions like Failed Back Surgery Syndrome and Diabetic Peripheral Neuropathy. This ECAP IDE study builds on prior research, reinforcing the potential of personalized biomarker-driven therapy.
Meanwhile, Dr. Harold Nijhuis’s research was groundbreaking as it objectively characterized the neurophysiology of the cervical and thoracic regions during spinal stimulation. His findings suggest that greater sensitivity in cervical spinal stimulation could lead to challenges like over- or under-stimulation. This underscores the necessity of precise dosing using the ECAP dose-controlled closed-loop approach to achieve sustainable long-term treatment results.
Saluda Medical's Vision for the Future
Jim Schuermann, President and CEO of Saluda Medical, articulated his enthusiasm about these developments, stating, "We are at a crucial turning point in the realm of spinal cord stimulation, illuminating a path where neurophysiological data and automation redefine standard practices. We envision a future where objective science and personalized treatment converge to enhance patient care for years ahead."
Advances in Patient Therapy
Dr. Pope expressed optimism regarding this novel approach, stating that the comprehensive understanding of ECAP biomarkers can lead to improved pain management strategies. The findings from the largest SCS IDE study instill confidence that customized therapies can yield essential pain relief across diverse patient populations, thereby fostering new breakthroughs in predicting patient responses to treatment and refining programming for optimal outcomes.
Saluda's Commitment to Neuromodulation
Recognition of the Evoke System during the NANS Annual Meeting reaffirms Saluda Medical's dedication to advancing the science of neuromodulation. By integrating empirical clinical evidence with objective metrics and automation, Saluda empowers clinicians to deliver tailored therapies that are efficient and effective for individuals experiencing chronic pain.
About Saluda Medical
Saluda Medical specializes in developing innovative solutions for chronic neurological disorders through its novel neuromodulation platform. Their closed-loop system measures neural responses, adjusting therapy in real-time according to patient needs. The Evoke® System is noted for its application in managing chronic pain conditions, showcasing clinically superior effectiveness as evidenced by multi-center studies published in renowned medical journals.
Frequently Asked Questions
What is the EVA™ platform developed by Saluda Medical?
The EVA™ platform is an automated spinal cord stimulation programming tool designed to enhance therapy effectiveness for chronic pain management.
What recent findings were shared about the Evoke System?
Recent research highlighted the Evoke System's ability to provide superior pain relief through personalized, biomarker-driven therapy.
Who presented the key findings during the NANS Annual Meeting?
Prominent researchers including Dr. Ajay Anthony and Dr. Jason Pope shared significant clinical findings regarding the use of the EVA™ platform and ECAP biomarkers.
How does Saluda Medical ensure effective therapy delivery?
Saluda Medical combines empirical clinical evidence and advanced neurophysiological metrics to personalize therapy for patients, maximizing efficacy and comfort.
What is the main goal of Saluda Medical's innovations?
The primary goal is to redefine standards in neuromodulation therapy, leading improved outcomes and enhancing the quality of life for patients with chronic pain conditions.
